Easton Pharmaceuticals Provides Update On Its Medicated Markets Partnership, Joint Initiatives And The Booming Medical Marijuana Climate In California For January 2015

HUMBOLDT, CA and TORONTO, ON--(Marketwired - February 09, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) Provides Medicated Markets partnership update, discloses joint initiatives and provides comments and opinions on the booming medical marijuana climate in California in January 2015

Easton announced its intention and formally entered the lucrative medical marijuana industry in the United States through its 40% ownership purchase of Medicated Markets International LLC, a major Medical Marijuana grower in the state of California. Medicated Markets International’s main business directive is the cultivation of marijuana for wholesale, in the state of California and other Legalized states. 100% of its current sales volume is sold in the State of California. As such wholesale price movements in Medical Marijuana rates in California directly impact Medicated Market’s bottom line.

In January wholesale prices in California for prices paid by current dispensaries serviced have risen an average of 15% depending on the strain. The average wholesale price sold by Medicated Markets in December 2014 was USD$1925 per pound while January 2015 prices averaged USD$2185 per pound. The rise in price is partly due to seasonal demand as well as the current robust nature of demand in California.

Medicated Markets maintains current operations in multiple counties in California, including Riverside County and Humboldt County (20 acres), with additional property to be slated in Mendocino County in the range of approximately 30 acre’s (outdoor greenhouse). This property should be in escrow by late February and close by March, an update on that specific detail will be provided once the property is in escrow. The reason Medicated Markets has diversified into multiple counties has been to remove dependence on any one counties restrictions on water use, as well as to guard against any single counties potential future ordinance changes. Two Master Growers for Medicated Markets LLC and their verifiable license numbers and addresses locations are stated below.

Mr. Miguel G Garcia #330471333 verifiable at http://mmic.cdph.ca.gov 22345 Comet Crt, Perris CA 92570

Mr. Matthew A Woods #081601791054518 http://verify.greenlifemedical.com 22945 Deprad St, Perris CA 92570

The locations listed above are currently active growing sites for nursery and strain development maintained by the master growers listed.

Revenue estimates for Medicated Markets facilities fiscal 2015 should be ready for presentation and disclosure on Monday February 16th; with details including exact strains planted this season, and harvest time lines. Questions related to current business posted to info@medicatedmarkets.com will also be answered. All questions need to be submitted by end of day Tuesday February 10th 2015 to be considered.

In other developments, a case involving a group of patients who allege that Health Canada’s MMPR program violates the constitution will begin trial on February 23, 2015. The case is being led by B.C. lawyer John Conroy and challenges rules set out by the government’s revamped medical marijuana program, including the ban on home grown marijuana and Marijuana products such as edibles and extracts. As Easton Pharmaceuticals Inc wish’s to develop site delivery of Marijuana product, and extracts for medicinal purposes in Canada and such maintains a vested interest in the outcome of these hearings.

Easton Pharmaceuticals, along with its partners, Medicated Markets International LLC is continually searching for synergistic opportunities to add to its current portfolio of Medical Marijuana related investments In US markets as well as Canadian and encourages communication with any and all interested parties.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs to treat cancer and other conditions that are in various stages of development with 3 of its OTC products to soon be ready for marketing and sale. Easton has completed an acquisition that grants a 40% ownership interest in Medicated Markets International LLC; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system, and has an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada, located in Ontario, Canada which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope,” “positive,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.